Chimeric antigen receptor T cell

European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World

Retrieved on:

Friday, June 11, 2021

Medicine, Clinical medicine, Branches of biology, Lymphoma, Gene therapy, Pediatric cancers, Chimeric antigen receptor T cell, Leukemia, Clinical trial, Kite Pharma, Cancer immunotherapy

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.

Key Points:

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.
Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy.
Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused.
In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.

European Hematology Association - Clinical Trial Efficacy of CAR-T Therapy in Patients with Diffuse Large B-cell Lymphoma Is Mirrored in the Real World

Retrieved on:

Friday, June 11, 2021

Medicine, Clinical medicine, Branches of biology, Lymphoma, Gene therapy, Pediatric cancers, Chimeric antigen receptor T cell, Leukemia, Clinical trial, Kite Pharma, Cancer immunotherapy

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.

Key Points:

In this study, we aimed to analyze patient characteristics and clinical outcome of 537 patients with diffuse large B-cell lymphoma who were registered in the DESCAR-T database.
Approximately 50 new patients were registered each month, demonstrating the success of CAR-T therapy.
Of the registered patients, CAR-T cells were ordered for 607 patients and 550 had been infused.
In conclusion, our analysis of the DESCAR-T registry confirmed the clinical trial efficacy of CAR-T therapy in the real world.

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Retrieved on:

Friday, June 11, 2021

Medical specialties, T cells, Clinical medicine, Medicine, RNA, RNA interference, Immune system, Lymphoma, Short hairpin RNA, Chimeric antigen receptor T cell, CD3

Filippo Petti, Chief Executive Officer of Celyad Oncology, commented, "We believe the initial data presented today are meaningful beyond the demonstrated clinical activity of CYAD-211.

Key Points:

Filippo Petti, Chief Executive Officer of Celyad Oncology, commented, "We believe the initial data presented today are meaningful beyond the demonstrated clinical activity of CYAD-211.
As we work to establish shRNA as a platform for developing allogeneic CAR T therapies, these early data from the IMMUNICY-1 trial are key.
Unfortunately, most patients eventually relapse and we observe shorter duration and depth of responses to treatments over time.
The trial is designed to evaluate proof-of-concept that shRNA-mediated knockdown of the CD3 can generate allogeneic CAR T cells.

CAR T Cell Therapy Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on:

Thursday, June 10, 2021

General Health, Pharmaceutical, Health, Health sciences, Medicine, Clinical medicine, Gene therapy, Drug discovery, Medicinal chemistry, Cancer immunotherapy, Chimeric antigen receptor T cell, Pipeline, Multiple myeloma, Therapy, Bluebird bio

The "CAR T - Cell Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "CAR T - Cell Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "CAR T-cell Therapy - Pipeline Insight, 2021," report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape.
CNCT19 is being developed by CASI Pharmaceuticals in collaboration with Juventas Cell Therapy.
It is a next-generation CAR T-cell therapy designed to maintain very potent and durable activity against BCMA, an antigen target expressed on essentially every multiple myeloma cell.

NEW LEADING-EDGE TREATMENT FOR LEUKEMIA NOW OFFERED AT NICKLAUS CHILDREN'S HOSPITAL

Retrieved on:

Thursday, June 10, 2021

Clinical medicine, Medicine, Medical specialties, Pediatric cancers, Gene therapy, Lymphoma, Chimeric antigen receptor T cell, Immune system, Leukemia, Children's Hospital Colorado, Nicklaus Children's Hospital, Acute lymphoblastic leukemia

The treatment, known as chimeric antigen receptor T-cell (CAR T) therapy uses a patient's own immune system cells to treat acute lymphoblastic leukemia (ALL) and B cell lymphomas.

Key Points:

The treatment, known as chimeric antigen receptor T-cell (CAR T) therapy uses a patient's own immune system cells to treat acute lymphoblastic leukemia (ALL) and B cell lymphomas.
The Nicklaus Children's Cancer and Blood Disorders Center is an approved treatment facility to deliver the FDA-approved CAR T-cell therapy to the pediatric population.
The Cancer and Blood Disorders Center at Nicklaus Children's Hospital, is the region's leader in the care of children with cancer and hematologic disorders.
Founded in 1950 by Variety Clubs International, Nicklaus Childrens Hospital is South Floridas only licensed specialty hospital exclusively for children, with nearly 800 attending physicians, including more than 475 pediatric subspecialists.

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

Retrieved on:

Thursday, June 10, 2021

Health sciences, Medical specialties, Branches of biology, Immunology, Drug discovery, Immune system, Single-chain variable fragment, Therapy, Antibody, Chimeric antigen receptor T cell

The partnership is a natural expansion of Vors mission to create eHSC therapies that unlock the potential of targeted treatments by protecting patients healthy cells.

Key Points:

The partnership is a natural expansion of Vors mission to create eHSC therapies that unlock the potential of targeted treatments by protecting patients healthy cells.
Rimas Orentas, Ph.D., who is a pioneer in CAR-T cell therapy, serves as Abound Bios Vice President for Cellular Therapy.
Abound Bio is an innovative and successful privately held biotechnology company with the mission of generating novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious diseases.
Abound Bio's industry-leading human antibody libraries offer size, diversity and developability advantages that incorporate different binder formats, including VH domains, scFvs and Fabs, into appropriate therapeutic platforms.

CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on:

Thursday, June 10, 2021

Health, Stem cells, Clinical trials, Health sciences, Medicine, Clinical medicine, Multiple myeloma, Drug discovery, Medicinal chemistry, Chimeric antigen receptor T cell, Therapy

The "CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape.
CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx.
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma

Retrieved on:

Thursday, June 10, 2021

Biotechnology, General Health, Pharmaceutical, Health, Clinical medicine, Medical specialties, Medicine, Lymphoma, Chimeric antigen receptor T cell, Gene therapy, Immune system, Leukemia, Genmab, Juno Therapeutics

Bristol Myers Squibb thanks the patients and investigators who are participating in the TRANSFORM clinical trial.

Key Points:

Bristol Myers Squibb thanks the patients and investigators who are participating in the TRANSFORM clinical trial.
All enrolled patients have large B-cell lymphoma and were relapsed or refractory within 12 months from CD20 antibody and anthracycline containing first-line therapy.
Breyanzi is a CD-19 directed chimeric antigen receptor (CAR) T cell therapy with a defined composition and 4-1BB costimulatory domain.
Bristol Myers Squibbs clinical development program for Breyanzi includes clinical studies in earlier lines of treatment for patients with relapsed or refractory LBCL and other types of lymphoma.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on:

Tuesday, June 8, 2021

Pharmaceutical, Health, Oncology, Lymphoma, Cancer, Clinical medicine, Medical specialties, Non-Hodgkin lymphoma, Hodgkin lymphoma, Chimeric antigen receptor T cell, Thyroid lymphoma

The "CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline landscape.
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Non-Hodgkin's lymphomadrugs segregated based on following parameters that define the scope of the report, such as:
There are approx.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

IASO Biotherapeutics and Innovent Biologics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

Retrieved on:

Tuesday, June 8, 2021

Among them, eight patients had extramedullary multiple myeloma (EMM) and one patient had complication with plasma cell leukemia.

Key Points:

Among them, eight patients had extramedullary multiple myeloma (EMM) and one patient had complication with plasma cell leukemia.
Ten patients previously received autologous hematopoietic stem cell transplantation (AHSCT), and 10 patients received murine BCMA CAR-T treatment.
The updated data reinforce the advantages and uniqueness of CT103A in the treatment of patients with relapsed/refractory multiple myeloma.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.